Medroxyprogesterone promotes neuronal survival after cerebral ischemic stroke by inhibiting PARthanatos
Our findings indicate that medroxyprogesterone effectively inhibits PARthanatos not by affecting the activity of PARP-1, but by directly binding to ERK and stabilizes the active phosphorylated ERK, thereby inhibiting AIF translocation. Furthermore, medroxyprogesterone shows potential as a neuroprotective agent for patients with CIS, potentially enhancing post-stroke recovery and reducing societal burdens.
Authors
- Yanfei Ding (ORCID: https://orcid.org/0000-0002-3460-1344)
- Xiaohui Xu (ORCID: https://orcid.org/0000-0001-7608-4114)
- Zhaohuan Zhang (ORCID: https://orcid.org/0000-0001-6882-9761)
- Chang-Ling Yue
- Yingxin Zhou (ORCID: https://orcid.org/0000-0001-7541-7327)
- Meng Chen (ORCID: https://orcid.org/0000-0002-2449-5904)
- Yuxin Shen (ORCID: https://orcid.org/0009-0004-1742-0797)
- Hai Huang (ORCID: https://orcid.org/0000-0002-5224-9911)
- Anni Hu (ORCID: https://orcid.org/0009-0004-5932-6192)
Institutions
- Wannan Medical College (CN)
- Shanghai University (CN)
- Second Military Medical University (CN)
- Shanghai Changzheng Hospital (CN)
- First Affiliated Hospital of Henan University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fphar.2025.1487436
- Citations
- 3
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.53
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province